Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Relaxant drug of the muscle with action on the Central Nervous System and chemically related to tricyclic antidepressants.
Indicated in muscle spasms of musculoskeletal origin.
Oral administration one to three times a day, maximum 2 weeks.
Its pharmacokinetic data (large volume of distribution and high percentage of protein binding) explain the very small passage to milk observed (Burra 2019).
No problems have been observed in two infants whose mothers took it for months since birth (Burra 2019).
A 16-day-old newborn whose mother took cyclobenzaprine, paracetamol and oxycodone had recoverable cardiorespiratory problems (Beauchamp 2019).
It is recommended to use the lowest effective dose possible.
Long-term treatments or those mothers who are nursing a newborn or premature infant would be prudent the use of a known safer alternative or with a shorter elimination half life.